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Abstract 
 
 Tuberculosis (TB) is a disease caused by the facultative intracellular species Mycobacterium 
tuberculosis (Mtb), one of humankind’s most ancient and successful pathogens. The eradication of Mtb 
infection has been a problem over the ages, due to pathogen’s ability to survive in host cells and escape 
the immune defense mechanisms. One efficient mechanism to kill pathogens occurs within 
macrophages, innate immune cells that use, among others, phagocytosis, a mechanisms by which the 
macrophage engulfs the bacteria in a structure called the phagosome which matures and in which a series 
of killing events will the clear pathogens. Specifically, the content of the phagosome will acquire 
proteolytic enzymes, as is the case of cathepsins, that will take relevant role in pathogen destruction at 
the low pH environment of the phagolysosome and, not less relevant, processing pathogen antigens to 
be presented to lymphocytes and therefore to expand the immune response. Recent studies revealed that 
Mtb is able to regulate cathepsins at the level of the gene expression and activity, increasing its survival 
inside macrophages. Cathepsins are regulated by their inhibitors, cystatins, which bind their active site 
and down-regulate cathepsins activity. Since Mtb was shown to down-regulate cathepsin activity we 
hypothesize that the cystatin pathway might be explored to improve the processes dependent on 
cathepsin activity such as pathogen destruction and antigen processing by type II HLA complexes, to 
counter the ability of Mtb to survive during infection. 
 In the first part of the study we target cystatin C, since it is described to be a major inhibitor of 
cathepsin S, an important cathepsin enrolled in pathogen clearance and antigen presentation. By 
silencing the mRNA of cystatin C we do hypothesized to prevent it from inhibiting cathepsins activation 
during several models of mycobacteria infection including the vaccine species Mycobacterium bovis 
bacillus Calmette-Guérin (BCG) and the non-virulent species Mycobacterium smegmatis infection. 
Overall, our results after cystatin C silencing, indicate an increase in proinflammatory responses by 
infected macrophages, concomitant with an increase of mycobacteria killing, and an improvement of 
the expression of HLA-DR receptors on the cell surface. 
 In parallel, we focused on the influence of protease inhibitors (PIs) used in HIV therapy, as an 
alternative model to cystatin silencing, to control cathepsin activity within macrophages during 
mycobacterial infections. We assessed the effects of saquinavir and ritonavir on the antigen presentation 
HLA class II complexes expression at the cell surface and on the mycobacterial killing/survival effects. 
We found notable interactions between the infected cells and the protease inhibitors, particularly 
saquinavir was observed to increase the expression of HLA-DR on the cell surface and increased 
mycobacterial killing, while ritonavir decreased HLA-DR expression on the surface and contributed to 
an increased mycobacterial survival. 
 Altogether our results show that by manipulating cystatin C expression in macrophages and/or 
the treatment of infected cells with PIs, leads to macrophage interference of cathepsins and therefore 
with macrophages defense mechanisms. Thus suggests that cystatins and PIs manipulation are a 
potential tool to improve the host cellular immunity against Mtb and be used as an host-targeted 
therapeutic. 
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Resumo  
 
A tuberculose é uma doença infeciosa que se desenvolve, na maioria dos casos, nos pulmões, 
causada por um agente patogénico intracelular facultativo do complexo Mycobacterium tuberculosis 
spp que inclui a espécie Mycobacterium tuberculosis (Mtb) e o Mycobacterium bovis. Apesar do 
desenvolvimento de antibióticos para terapêutica e do melhoramento da qualidade sanitária ao longo 
dos anos, nos dias de hoje a tuberculose é considerada uma das 10 maiores causas de morte por doença 
infeciosa. Isto deve-se à capacidade adaptativa deste agente patogénico, que levou ao aparecimento de 
formas multirresistentes a antibióticos, tornando difícil a sua irradicação no mundo. 
A capacidade adaptativa do M. tuberculosis levou à aquisição de mecanismo que contornam os 
mecanismos de defesa do hospedeiro. O sistema imunitário responde ao contacto pelos microrganismos, 
iniciando-se o recrutamento de células imunes inatas como, os macrófagos e células dendríticas, os quais 
são a primeira linha de defesa celular do hospedeiro. Os macrófagos têm a capacidade de destruir 
conteúdo extracelular através de um processo denominado fagocitose, este processo inicia-se quando os 
macrófagos reconhecem e internalizam a bactéria a vesícula chamada fagossoma, que passa por 
diferentes estádios de maturação através de uma série de fissões e fusões parciais do organelo com 
endossomas tardios. O estádio final de maturação após fusão com os lisossomas primários dá origem ao 
fagolisossoma. O conteúdo desta vesicula possuí enzimas hidrolíticas que no pH acídico desse lúmen 
ficam ativadas, proporcionando condições ambientais ótimas para a degradação dos microrganismos 
internalizados. Contudo, Mtb consegue escapar a este sistema, impedindo a sua maturação e bloqueando 
no seu nicho ao estado de vesicula fagossomal imatura. Deste modo persiste intracelularmente limitando 
a sua interação com estes mecanismos degradativos o que lhe permite sobreviver e inclusivamente 
replicar-se em macrófagos de granulomas nos pulmões. Assim, na maioria dos casos o balanço entre a 
sobrevivência, a replicação da bactéria e o recrutamento e ação das células do sistema imune leva a que 
a infeção fique confinada a uma estrutura denominada granuloma que permite o seu controlo. O 
indivíduo encontra-se infetado mas não demonstra ter sintomas de doença, existindo uma 
doença/infeção latente que pode ser ativada em qualquer momento que o organismo desenvolva 
imunodepressão. 
Um grupo muito importante de enzimas proteolíticas que se encontram no lúmen das vesículas 
fagocitárias, são as catepsinas. Estas hidrolases lisossomais clivam as ligações peptídicas levando à 
degradação proteica e atuam no processamento de péptidos para apresentação de antígenos, contribuindo 
para a morte de agentes patogénicos. Foi observado em estudos que uma das catepsinas com maior nível 
de expressão durante a infeção, na fagocitose e nos macrófagos, é a catepsina S, cuja principal função é 
apresentar antigénios ao complexo principal de histocompatibilidade classe II (MHC II em ratinho ou 
HLA II em humanos). Apesar das catepsinas serem bastante expressas durante a infeção, elas são 
controladas pelos seus inibidores naturais as cistatinas, que se ligam ao sítio ativo das catepsinas inibindo 
a sua atividade proteolítica. Contudo, existem evidências que o bacilo da tuberculose interfere com a 
atividade proteolítica do macrófago para aumentar a sua sobrevivência durante a infeção, diminuindo a 
atividade das catepsinas. O mesmo foi demonstrado ao nível da expressão genética das cistatinas, mas 
não existem estudos que comprovem que esse mecanismo afeta também a atividade inibitória das 
cistatinas nem o efeito no controlo da infeção. Uma possível via para contornar a reação adversa da 
micobactéria, seria através da manipulação das cistatinas, tornando-as interessantes alvo de estudo. 
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A tuberculose é uma doença altamente associada à infeção pelo vírus da imunodeficiência 
humana (HIV) uma vez que a consequente imunodeficiência provocada pela ação do vírus leva à 
disrupção do granuloma que contém a infeção por Mtb e disseminação do bacilo pelos tecidos. Um 
conjunto de moléculas utilizadas para o tratamento do HIV, são os inibidores da protease viral (IP). Já 
foi demonstrado experimentalmente que os IP influenciam a atividade das catepsinas durante a infeção 
pelo HIV. Assim sendo, estes inibidores podem ser potencialmente úteis na manipulação das catepsinas 
durante a infeção por outros agentes patogénicos, incluindo o Mtb a fim de contribuir para controlar 
esses infeções. 
O principal objetivo deste estudo foi investigar a interação entre cistatinas, Mtb e macrófagos, 
usando as cistatinas como ferramenta para manipular a proteólise por catepsinas durante a infeção e 
reforçar a resposta do hospedeiro na eliminação dos patogenos. 
Neste estudo, usamos metodologias de RNA de interferência (‘small interfering RNA; siRNA’) 
específicos para silenciar o RNAm para a cistatina C durante a infeção por Mycobacterium bovis bacillus 
Calmette-Guérin (BCG) e Mycobacterium smegmatis. Esta cistatina é expressa em todos os tecidos e é 
o maior inibidor natural da catepsina S.  
Numa primeira fase, foi estudada a expressão génica da cistatina C durante a infeção por 
micobactérias através de PCR quantitativo (qPCR). Os nossos resultados mostram que a eficiência do 
silenciamento da cistatina C pela técnica usada em macrófagos, é cerca de 50% na redução dos níveis 
do RNA mensageiro comparativamente com os níveis obtidos no controlo, ou seja, em macrófagos nos 
quais foi usado um siRNA controlo inespecífico (scramble).  
As consequências do silenciamento ao nível da resposta inflamatória, especificamente por 
análise de ELISA da secreção de interlucina-1β (IL-1β) em macrófagos não infetados, 
comparativamente com macrófagos infetados com M. bovis BCG e M. smegmatis, indicam que com 
silenciamento da cistatina C concentrações de IL-1β aumentaram ainda mais. Também foi possível 
verificar diferenças entre macrófagos infetados com M. bovis BCG e M. smegmatis com e sem 
silenciamento da cistatina C. 
A análise da expressão dos marcadores apresentadores de antigénios à superfície dos 
macrófagos foi feita através da citometria de fluxo. O antigénio leucocitário humano tipo II (type II 
human leukocyte antigen, HLA-DR) foi usado nesta experiência pela sua capacidade de apresentar 
péptidos de bactérias fagocitadas aos linfócitos T. Os níveis de expressão foram analisados em 
macrófagos não infetados e macrófagos infetados com M. bovis BCG e M. smegmatis, com e sem 
silenciamento da cistatina C. Baixos níveis de expressão da HLA-DR foram observados em macrófagos 
infetados com M. bovis BCG, um efeito descrito em micobactérias patogénicas e que é comum quer ao 
Mtb quer ao BCG. No entanto, os macrófagos silenciados apresentaram uma restituição desses níveis 
da expressão da HLA-DR para níveis semelhantes a M. smegmatis, melhorando assim a resposta imune. 
A sobrevivência das micobactérias durante a infeção foi estudada através da contagem de 
unidades formadoras de colónias (colony-forming unit, CFU) em macrófagos infetados com M. bovis 
BCG e M. smegmatis, com e sem silenciamento da cistatina C. A infeção por micobactérias em 
macrófagos leva a um aumento da sua sobrevivência, mas ao manipularmos a cistatina C, silenciando-
a, observamos que existe uma redução da sobrevivência das micobactérias apontando possivelmente 
para um aumento da atividade proteolítica e capacidade de matar o patogeno.  
Em paralelo, macrófagos infetados foram tratados com as inibidoras da protease viral do HIV 
(IP), especificamente saquinavir (SQV) e ritonavir (RTV), para estudar o seu efeito na modulação da 
resposta do hospedeiro após a infeção com M. bovis BCG. Foram analisados ao nível: da resposta 
inflamatória, através da análise da secreção da citoquina IL-1β; da expressão dos apresentadores de 
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antigénios à superfície, usando o HLA-DR como antigénio de análise, e na sobrevivência da 
micobactéria através da contagem de unidades formadores de colónias. 
Quando as células infetadas foram tratadas com os IP, os resultados mostram que ao nível da 
resposta inflamatória, existe um aumento abruto da secreção da IL-1β quando infetadas com 
micobactéria comparativamente com as células não infetadas. No entanto, observaram-se diferenças 
significativas entre os tratamentos em células infetadas. No tratamento com RTV em macrófagos 
infetados, observou-se um maior aumento da secreção de IL-1β do que nos macrófagos infetados 
tratados com SQV. 
Na análise da expressão dos marcadores apresentadores de antigénios, os tratamentos levam a 
uma variação significativa da expressão do HLA-DR. Contudo verificou-se que o saquinavir modula a 
resposta positivamente, aumentando os níveis de expressão da HLA-DR à superfície da célula, enquanto 
o ritonavir diminuí os efeitos do mesmo. 
A contagem de unidades formadoras de colónias permitiu observar que ao longo do estudo, o 
tratamento com saquinavir diminuí a sobrevivência do M. bovis BCG, em contraste o tratamento com 
ritonavir aumenta significativamente a sobrevivência. 
 
No conjunto, os resultados obtidos no silenciamento da expressão da cistatina C levaram a um 
aumento da resposta pró-inflamatória por macrófagos infetados, tal como um aumento da capacidade 
do macrófago de expressar moléculas apresentadoras de antigénios à superfície da célula e um aumento 
na morte intracelular das micobactérias. Isto sugere que a manipulação das cistatinas, que regulam 
negativamente as catepsinas, podem ser uma ferramenta viável para potenciar as células hospedeiras, 
no controlo da atividade proteolítica melhorando a resposta imune contra a infeção e eliminarem as 
micobactérias. Os resultados obtidos pelos IP mostram que células tratadas com ritonavir diminuem a 
capacidade de expressão de apresentadores de antigénios e aumentam a sobrevivência da micobactéria, 
enquanto o tratamento com saquinavir aumentou a capacidade de expressar moléculas apresentadoras 
de antigénios à superfície e um aumento da morte das micobactérias, tornando o saquinavir um potencial 
alvo de estudo para o desenvolvimento de uma nova terapia contra Mtb. 
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1. Introduction 
 
Tuberculosis (TB) is an infectious disease caused by the facultative intracellular bacteria of the 
Mycobacterium tuberculosis Complex (MTC) 1. The disease occurs in the lungs by inhalation of airborne 
droplets containing the bacilli, settling in the respiratory system of the host and infecting other 
individuals using as propagation vehicle the cough of the host 2. It caused 1.3 million deaths in 2017, 
becoming one of the top 10 leading causes of death and the main cause of death by a singular infectious 
agent worldwide 3. Tuberculosis diagnosis had a swift development during the last 10 years, however 
even with TB therapy which intends to avoid complications and mortality, the number of new cases 
increased to 5.7 – 5.8 million per year 4. These numbers reveal the importance of knowing and 
understanding the host defense mechanisms and the interactions between the pathogen and the cells of 
the immune system, in order to create new tools against M. tuberculosis and decrease the mortality of 
this disease. 
 
1.1. MTb infection – transmission and the immune system  
 
M. tuberculosis (Mtb) was presented for the first time to the Physiological Society of Berlin in 
1882 by Robert Koch, who showed evidences for the isolation of a living rod-shaped organism causing 
the disease (TB) 5. Mycobacteria are Gram-positive and acid-fast, they are aerobic and rod shaped and 
comprising a peptidoglycan-arabinogalactan polymer with covalently bound mycolic acids which are 
components of their walls 6. This provides an extraordinary efficient permeability barrier to noxious 
compounds and many drugs. Treatments affecting mycolic acid biosynthesis and the production of 
extractable lipids resulted in an increase of cell wall permeability which drastically decrease the 
virulence of Mtb 7. 
M. tuberculosis dynamics within the host begin by inhalation of bacilli expelled by an individual 
with active tuberculosis and installment of the bacteria in the respiratory tract, more specifically in the 
lungs. When in the lungs the immune system is activated, macrophages and dendritic-cells (DC) are 
recruited being the first line of defense of our immune system. After their activation they are able to kill 
intracellular bacteria and participate in a protective T helper cell type 1 (Th1) response 8. 
Macrophages are recruited to the infection site, participating in the formation of the granuloma 
that arises in response to a persistent stimulus 9. Granulomas are organized aggregates of immune cells 
in which macrophages and T cells play the central role. The structure of the granuloma develops with 
the fusion of macrophages resulting in multinucleated giant cells and lipid-filled foamy macrophages 
surrounded by a ring of lymphocytes encapsulated in a fibrotic cuff 10,11. The structure main function is 
to contain the pathogen, providing an important niche during the infection. Granuloma differs between 
active and latent form of infection. In latent infection the center of granuloma is made of infected 
macrophages and other cells and fibrotic granulomas without bacilli also exist. In active disease is found 
granulomas composed of dead and alive macrophages at the center and few lymphocytes, necrotic 
neutrophilic cells, giant foam cells and epithelioid macrophages. The state of the granuloma is crucial 
for control of bacterial proliferation. In latent infection, Mtb resides in the hypoxic center, rich in lipids, 
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but in active disease, Mtb can replicate in peripheral oxygenated areas. Deficiency on some cytokines 
can lead to granuloma malformation leading to bacteria proliferation 12,13.  
However, Mtb is able to resists inside the granuloma and persist in the lungs, escaping using its 
own strategies against the granuloma and proliferate to the lung tissue, leading to active pulmonary 
tuberculosis.  
  As pathogens have elaborated defense and survival strategies to persist during infection and 
replicate in a host organism, likewise the host organism developed strategies for their protection such as 
phagocytosis, strict control over the production of proinflammatory and anti-inflammatory cytokines, 
apoptosis, and others. The alveolar macrophages internalizing and exposing pathogens to the acidic and 
hydrolytically active environment of the phagosome. This environment takes an important role to 
process and present peptide antigens derived from bacterial degradation, to T lymphocytes to major 
histocompatibility complex class II (MHC II) molecules 14. However, this pathogen survived by 
avoiding macrophages mechanisms and by replicating within these cells.  
Macrophages are activated by CD4+ and CD8+ T cells, to enhance their antimicrobial effects. 
They recognize microbe-associated molecular patterns (MAMPs) of the bacteria via pattern recognition 
receptors (PRRs) being the responsible to initiate the innate and adaptive immune response to Mtb 15.  
There are cytokines that potentiate the action of the cells of the immune system. Bacteria 
lipopolysaccharide (LPS) activated macrophages which release of proinflammatory cytokines like: (1) 
TNF-α, that contributes to inflammation and granuloma formation; (2) IL-1β, involved in the immune 
response such as TNF increased secretion, neutrophil chemotaxis, endothelial activation; (3) IL-6, and 
IL-12 working as synergistic activity on inflammatory pathway and to amplify this response leading to 
antigen presentation and IFN-γ secretion by CD4+ and CD8+ T-helper cells 16,17. 
 
1.2. Phagocytosis 
 
An important innate immune mechanism performed by macrophages to eliminate bacteria is 
phagocytosis. Phagocytosis begins when the pathogen is recognized by host cellular receptors that 
promote its internalization in a vacuole called the phagosome. Then the phagosomal membrane 
composition changes becoming accessible to early endosomes, and by fusion and fission events, its 
content matures and becomes able to fuse with late endosomes. After these events, it merge with 
lysosomes forming a phagolysosome. In the phagolysosome several aggressions are delivered to the 
bacteria: (1) the vacuolar H+ - ATPase - whose activity leads to an acidification of the phagolysosomal 
lumen to a pH around 5; (2) release of reactive oxygen species (ROS) produced by NADPH-oxidase 
and reactive nitrogen species (NOS) produced by nitric oxide synthase; (3) increased activity of 
proteolytic enzymes such as cathepsins and also of lipolytic enzymes. This deadly combination 
promotes the bacteria degradation. However Mtb is capable to counter these macrophages mechanisms 
and survive18–21.  
There are many pathways that Mtb use to escape from the degradative aspects of the phagocytic 
process. The majority of them involve inhibition of the maturation of phagolysosomes. These may occur 
by: (1) inhibiting early endosome maturation to late endosome by acting above Rab GTPase network; 
(2) inhibiting the phagosomal acidification by secreting PtpA to inhibit H+ ATPase complex; (3) 
blocking the fusion with lysosomes avoiding contact with degrative lysosomal enzymes through 
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recruitment of Coronin 1 to the phagosomal surface; (4) inhibiting autophagy using virulence 
components to overexpressing macrophages to regulate the apoptotic response 22,23.  
 
Since Mtb is able to modify the phagosomal environment by interfering with several 
mechanisms of the macrophages, they are also interfering with antigen presentation by inhibiting this 
system. Toll-Like receptors (TLRs) are innate PRR receptors on the macrophages surface. They 
recognize Mtb, and produce proinflammatory cytokines required to control Mtb infection and the 
activation of CD4+ T cell. During this process, proteases degrade bacteria into peptide antigens that are 
loaded to MHC class II and induce a CD4+ T cell response and IFN- γ is expressed in control the 
infection. IFN- γ is important in this process not just by promoting effector mechanisms for containing 
pathogens but to induce MHC class II molecules.  
Mtb infected macrophages decrease MHC class II expression and antigen presentation, and it’s 
possibly related with mycobacterial lipoproteins which inhibit MHC class II molecule expression. These 
lipoproteins are agonist of TLR2 and MHC class II expression which antigen presentation are dependent 
of this receptor, prolonged TLR2 signaling may inhibit MHC class II antigen processing and 
presentation 24–26,27.  
 
1.3. Cystatins and Cathepsins 
 
During phagolysosome formation, the lysosome fuses with the phagosome, integrating 
components of its content such as degradative lysosomal enzymes. These enzymes contribute to lower 
pH and are involved in many processes as protein degradation, autophagy, direct pathogen killing, 
antigen presentation, among others. Thus, pathogens encased in macrophages phagosomes can be 
degraded by hydrolases such as cysteine proteases which are preponderant among lysosomal proteases. 
Cysteine proteases, or cathepsins, irreversible cleave peptide bonds exhibiting broad specificity, 
cleaving their substrates preferentially after basic or hydrophobic residues and possessing a multitude 
of substrates consistent with their roles in intracellular protein degradation. There are three groups of 
cathepsins found in humans denominated according to the amino acid residue at the proteolytic site: 
aspartatic proteases, cathepsins D and E; serine proteases, cathepsins A and G and the cysteine proteases, 
cathepsins B, C, F, H, K, L, O, S, V, X and W. Some of these cathepsins interact with Mtb, more 
specifically B, D, G and S 28–32.  
One particularity of almost all cathepsins is they have optimal activity at acidic pH and reduced 
or no activity at neutral and non-acidic pH. Cathepsins increase their activity in late endosomes and 
lysosomes which haves acidic pH content, important against intracellular bacteria. However, cathepsin 
S (Cat S) is an exception being capable to maintain its activity at neutral pH 33. 
In the human lungs, were found high levels of Cat S expression. This particular protease 
maintains its activity and stability at neutral pH, and its main function is in antigen processing and 
presentation having high expression levels during phagocytosis and in antigen-presenting cells such as 
macrophages 31,32,34. Cathepsin S is involved in the processing of maturation of MHC class II molecule. 
It was shown in Mycobacterium bovis spp. Bacille Calmette-Guérin (M. bovis BCG) infected cells  that 
when Cat S  expression was inhibited there was a decrease of MHC class II expression in macrophages, 
suggesting that by manipulating Cat S expression we are interfering with antigen presentation 
mechanism 31,32,35. 
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One important natural regulator of Cat S is cystatin C (CST C), a cysteine peptidase inhibitor, 
which binds reversibly to proteases at their active site, thus competing with the substrate, down-
regulating its activity. 
Cystatins come from a superfamily of evolutionary related proteins, each consisting in at least 
one domain of 100-120 amino acid residues with conserved sequence motifs. They are found in all living 
organisms (mammals, nematodes, arthropods etc.), and act in multiples biological processes as 
regulation of hormone processing, inflammation, antigen presentation and T-cell dependent immune 
response and modulators of proteolytic activity against bacterial and viral infection 36.  
This superfamily is divided by its structure in three families: Type I cystatins, known as Stefins 
(Stefins A and B), are polypeptides of 98 amino acid residues without disulfide bonds nor carbohydrate 
side chains and with one cystatin domain. They are mainly detected intracellularly acting as inhibitors 
of cysteine proteases. Type II cystatins, cystatins C, D, E/M, F, S, SA, SN, CRES, testatin, cystatins 
11, 12, 13 and 14, are bigger than type I cystatins with a single-chain polypeptides with 120 amino acid 
residues and have two conserved disulfide bridges. They can be secreted to extracellular space through 
the membrane cell by a signal peptide enhance their concentrations extracellularly. Type III cystatins 
are the most complex of all. They have approximately 350 amino acid residues, eight disulfide bonds 
and three type II cystatin domain. They are kininogens, intravascular proteins which are involved in the 
processes of protection against leaking lysosomal cysteine proteases 37–40. 
 
The molecular constitution of cystatins makes them tight-reversible binding protein inhibitors, 
and it is their structure that allows the manipulation of cathepsins. They have a long five-turn α-helix 
and a five-stranded antiparallel β-pleated sheet, with an additional helix. These suggested a three 
conserved regions: the amino terminus and two hairpin loops, which together create a wedge-shaped 
edge cystatin structure highly complementary to the active-site of cathepsins, blocking them. 40,41 
 The interaction between cystatins and their target proteases is determined by the differences in 
the structures of the interacting regions of the enzymes, which differ between every type of cystatins. In 
type I cystatins case, Stefin A is strongly related with the tissues in the first-line of defense, like the skin 
immune system, and it is highly expressed in follicular dendritic cells of germinal centers in secondary 
lymphoid organs, being able to prevent apoptosis 40,42. On the other hand, Stefin B is expressed in all 
human cells but its expression is increased by lipopolysaccharide (LPS) stimulation in response to 
bacterial infections 40,43. Type II cystatins act in different ways to help the immune system, but cystatin 
F and C have high expression in principal cells of the immune system. Cystatin F is found at dimeric 
and monomeric forms in dendritic cells, T cells and NK cells, regulating the activity of cathepsins by 
the endosomal/lysosomal pathway, but it is only activated when there is proteolytic cleavage at the N-
terminus converting it from dimer to monodimer and thus becoming capable to inhibit its main targets, 
cathepsins F, H, K, L, S and V 44,45. A feature of this cystatin is that it can be activated in its inactive 
dimeric form by inhibiting mannose-6-phosphate, which allows proteases to be trans-regulated in cells 
that do not express cystatin F 46. However, the most abundant cystatin found in a variety human tissues, 
cells types and body fluids is cystatin C. 
Cystatin C has a molecular mass of 13,343 Da and its encoding gene is a house-keeping gene, 
acting as an emergency inhibitor, neutralizing redundant proteolytic activity outside cells. Thus, it is 
considered the major inhibitor of cathepsins since its ability to bind tightly to the active-site of 
cathepsins, more specifically Cat B, H, L and S 47. It was also shown interaction between CST C and 
Cat K, where CST C regulate Cat K which acts in the degradation of the bone matrix 48. Many studies 
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suggest CST C strongly regulate cathepsin S activity it was shown in Sjögren’s Syndrome patient tears 
where is a reduction of CST C activity and an increase of Cat S activity changing tear composition 49. 
Beyond interfering in proteolytic activity by inhibit cathepsins, cystatin can also be involved in the 
production of reactive nitrogen species (NOS) in macrophages which is an important mechanism against 
microorganism, as previously mentioned. Some studies suggest that the combination of cystatin C and 
IFN-γ induced production of NOS promoting pathogen killing 38.  
Cystatin C is implicated in several diseases: it’s a marker of glomerular filtration rate and the 
kidney function 50; it’s involved in systemic lupus erythematosus inflammation process; cerebral 
amyloid angiopathy 51; promotes atherosclerosis; it’s involved in Alzheimer’s disease; among others. 
This cystatin is also related with Mtb infection. One of the mechanisms of Mtb to inhibiting phagosome 
maturation is to avoid the contact with cathepsins. Previously studies shown the treatment with cystatin 
leads to an increase of Mtb survival rate in macrophages. That suggest a down-regulation of cathepsins 
in macrophages which consequently promotes Mtb survival 31. Since CST C is a natural inhibitor of Cat 
S, this is a possible tool against Mtb infection. 
 
1.4. Immunodepression, HIV and antiretroviral therapy  
 
Tuberculosis and human immunodeficiency virus (HIV) are the main important infectious diseases 
with impact in resource-limited countries. In 2012, was estimated that 1.1 million of people were Mtb-
HIV co-infected 52. Tuberculosis and HIV act against the immune system. The co-infection is benefic 
to both diseases, HIV increases the risk of Mtb progression and Mtb increases the replication of the virus 
53.  
 Some treatments against the HIV involve protease inhibition. It was already shown in some 
studies that HIV proteases+ inhibitors affect cathepsins during HIV infection 54. In addition, it has been 
shown that Highly Antiretroviral Therapy (HAART), an HIV treatment, could decrease the impact on 
the immune system in the early stage of Mtb infection 55. 
The human immunodeficiency virus (HIV) is a chronic infection leading to the acquired 
immunodeficiency syndrome (AIDS). It is estimated that almost 37 million people are living with this 
infection 56. This infection has impact in the immune system leaving it compromised, and increases the 
probability of acquire other infections or diseases 57. A customized combination of anti-retroviral drugs 
is a therapeutic strategy to delay the infection progress, strategy known by Highly Antiretroviral Therapy 
(HAART). This combination is made by nucleoside reverse transcriptase inhibitors (NRTIs), non-
NRTIs (nNRTIs), integrase inhibitors and protease inhibitors (PIs) 58. Like MTb infection, HIV can 
infect macrophages in the lungs and interfere with the secretion of  proinflammatory cytokines, such as 
type I interferons, IFN-γ and TNF- α which contribute to disease control in both cases 59. In Mtb-HIV 
co-infection, was shown that cytokines production by Mtb-activated macrophages enhance replication 
of HIV-1 60.  
Recent studies showed a reduction of mortality in Mtb-HIV co-infected patients during HAART 
regimen. Since macrophages are common to both diseases, and one defense mechanism against 
pathogens is proteolytic activity, the PIs from HAART could be acting in both diseases changing  the 
proteolytic activity reducing both infections 61.  
Macrophages and DCs are both antigen presenting cells, they indeed cross-present exogenous 
antigens. One way to do cross-presentation is by endosomes or phagosomes, where proteins are partially 
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degraded by cathepsins and are presented to MHC-I 62,63. Inhibited proteolytic activity breaks the role 
of cross-presented antigens with a consequent the increase of infection.  
During HIV infection the PIs block the HIV aspartyl protease not allowing the cleavage of HIV 
Gag-Pol polyprotein and consequently the conversion of HIV particles into mature infectious virions 64. 
PIs like ritonavir (RTV) and saquinavir (SQV) also inhibit the proteolytic activity of the proteasome and 
consequently intracellular accumulation of polyubiquitinated proteins 65,66. 
Saquinavir was the first-generation of HIV protease inhibitors based on hydroxyethelene and 
hydroxyethelamine isosteres 64. Another developed PI was Ritonavir, a potent inhibitor of cytochrome 
P450 3A and inhibitor of p-glycoprotein efflux pumps. Ritonavir in HAART, is used more frequently 
as a booster to increasing SQV absorption and decreasing the metabolism of SQV allowing for larger 
bioavailability of SQV 67,68.  Both anti-retrovirals are capable to bind the active site of proteases, 
inhibiting them, similarly to how they inhibit HIV proteases. Recent studies showed that SQV and RTV 
have a strong effect on cathepsins activities. RTV induced a reduction of cathepsin activities while SQV 
enhanced them 54. These results suggest the hypothesis of using SQV and RTV during MTb infection to 
manipulate the proteolytic activity of human cathepsins to reduce the Mtb survival and improve other 
aspects of the immune response. 
 
 
 
Objective 
 Macrophages use cathepsins to destroy the bacteria and process their antigens, but Mtb interferes 
with these mechanisms in favor of its survival. Understanding how these proteolytic mechanisms 
respond to infection will provide a valuable insight to modulate the immune response to tuberculosis. 
The main goal of this thesis is to modulate the phagosomal proteolytic activity in macrophages infected 
with Mycobacterium bovis BCG by manipulating the natural inhibitors of cathepsins, the cystatins, or 
by treatment with protease inhibitors used in HIV therapeutic. 
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2. Materials and Methods 
 
2.1. Cell lines and culture conditions 
 
a. Monocyte isolation 
CD14 + monocytes were isolated from buffy coats from healthy donors provided by national 
blood institute (Instituto Português do Sangue e da Transplantação, Lisboa, Portugal).  
Buffy coats were diluted ½ with MACS buffer containing EDTA 2 mM (Gibco), 0.5 % 
inactivated fetal bovine serum (FBS) (Corning), phosphate-buffered saline (PBS) pH 7.2 (Gibco) 
Leukocytes were separated by density gradient centrifugation (800 x g, 20 min) using Ficoll-Paque (GE 
Healthcare Life Science). This gradient leads to the formation of a top layer of plasma, a second layer 
where leukocytes are found, a third layer of Ficoll-Paque and at last the densest layer composed of 
erythrocytes. The leukocyte layer was recovered and the cells were resuspended in MACS buffer, and 
centrifuged at 500 x g for 10 min. The resulting supernatant was rejected. Cells were resuspended in 
MACS buffer, centrifuged (500 x g, 5 min) and the resulting cells pellet was resuspended in MACS 
buffer. CD14+ were isolated by incubation of the resuspended pellet with Micromagnetic beads coated 
with CD14+-specific antibodies (Miltenyi Biotec). Cells were then separated using with a magnetic 
column. Following separation, the cells were counted and their viability was assessed by trypan blue 
exclusion staining. 
 
b. CD14+  differentiation into Macrophages (Mø) 
CD14+ cells were cultured for 3 h in Roswell Park Memorial Institute medium (RPMI) (Gibco) 
complemented with 1% glutaMAX (Gibco) and 1% HEPES buffer (Hyclone) and allowed to adhere to 
the bottom of the wells. Following 3 h the medium was supplemented with 1:1 proportion of fresh 
medium in order to achieve a final concentration of 1% glutaMAX, 1 % HEPES buffer, 10 % FBS, 1 % 
sodium pyruvate (Hyclone), 1 % penicillin- streptomycin (Gibco), 0.1 % β-mercaptoethanol (Gibco) 
and macrophages colony-stimulating factor 20 ng/mL (M-CSF). Fresh complete medium, as above, was 
added again at the 4th day of differentiation and left until the 7th day following which were ready to be 
used. 
c. Bacterial cultures 
Mycobacterium bovis bacillus Calmette-Guérin (BCG) containing a GFP encoding plasmid 
(GFP), and Mycobacterium smegmatis part of the mycobacteria library of our research unit (Host-
Pathogen Interaction Unit, iMED.ULisboa) were grown in Middlebrook 7H9 medium (Difco) 
supplemented with OADC enrichment (Difco) and 50 µg/ml hygromycin.  
 
2.2. Infection of Mø 
 
Bacteria cultures on exponential growth phase were centrifuged (3000 x g, 5 min), washed in 
phosphate-buffered saline (PBS) (Gibco) and centrifuged again (3000 x g, 5 min). Following that they 
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were resuspended in RPMI complete medium (without antibiotics) and submitted to an ultrasonic bath 
(5 min) to disrupt the bacterial clumps. Remaining clumps of bacteria were removed by a short spin 
(500 x g, 1 min). The resulting suspension was quantified measuring optical density at 600 nm (OD600) 
to determine the concentration of bacterial cells in the suspension. Cells were washed with PBS and 
incubated with mycobacteria at MOI 2 for 3 h at 37° C in 5 % CO2. Following incubation, cells were 
washed with PBS and fresh complete medium was added and cells were incubated at 37º C in 5% CO2 
for the rest of the experiments. 
 
2.3. RNA extraction 
 
Mø were seeded in 12-well plates at a density of 6 x 105 Cells/well and after infection RNA was 
extracted using the NZY Total RNA Isolation kit (NZYTech) and following manufacturer instructions. 
RNA bounded to the silica membrane column was eluted and its quantity and quality was determined 
by measuring the 260/230 and 260/280 nm absorbance ratios using NanoDropTM 1000 
spectrophotometer. 
 
2.4. Quantitative Real-Time polymerase chain reaction (qRT-PCR) 
 
The qRT-PCR was performed using NZY qPCR Green Master Mix (2x), ROX (NZYTech) 
following the manufacturer protocol. To synthesize cDNA from RNA, was used 2 µg of total RNA for 
cDNA synthesis performed according to NZY First-Strand cDNA synthesis Kit (NZYTech) protocol. 
qRT-PCR was performed using NZY qPCR Green Master Mix and the primers (Thermo Fisher 
Scientific) described in Table 1 at a final concentration of 0.5 μM. The qPCR reaction proceeded as 
follows: 1 cycle of 95 ºC for 10 min, followed by 40 cycles of 95 ºC for 15 s, 60 ºC for 30 sec and, 72 
ºC for 30 sec. The mRNA expression profiles were normalized with respect to GAPDH (Glyceraldehyde 
3phosphate dehydrogenase). The qRT-PCR was performed using an Applied BiosystemsTM  
QuantStudioTM  7 Flex Real-Time PCR System.  
Table 2.1: Primers used in qRT-PCR 
Target Gene Primer Sequence (5’-3’) 
 
Cystatin C 
Forward CAACAAAGCCAGCAACGACAT 
Reverse AGAGCAGAATGCTTTCCTTTTCAGA 
 
GAPDH 
Forward AAGGTGAAGGTCGGAGTCAA 
Reverse AATGAAGGGGTCATTGATGG 
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2.5. Transfection 
 
The transfection with siRNA anti-cystatin C (Thermo Scientific Dharmacon ON-Target plus 
smart pool) was performed using the ScreenFect®A and following the manufacturer’s instructions.  
Cells were already adherent in a 96-well plate from the differentiation. In separate, 0.45 μl of 
ScreenFect®A were diluted in 10 μl of Dilution Buffer per well and 0.25 μl of siRNA anti-cystatin C 
were diluted in 10 μl of Dilution buffer per well. Diluted ScreenFect®A and siRNA anti-cystatin C were 
mixed and incubated for 20 min at room temperature to allow the complex formation. Following that 
were added 100 μl of freshly detached per well and resuspended the cells with the complexes. The plates 
were maintained at 37 ºC in a 5 % CO2 incubator overnight (16 – 18 h). 
 
2.6. Flow cytometry  
 
Mø were seeded in 48-well plates at density of 1.5 x 105 cells/well. Following infection with 
mycobacteria, HLA-DR expression were measured using HLA-DR specific antibody conjugated with 
PerCP (Biolegend). Briefly, cells were detached from the wells incubating with Accutase for 15 min at 
4 °C and then centrifuged (500 x g, 5 min). The cell pellet was resuspended in 4 % paraformaldehyde 
for 30 min in the dark for cell fixation. Cells were washed with PBS containing 2 % of FBS and EDTA 
2 mM and then incubated with the HLA-DR specific antibody for 30 min at 4 °C. The samples were 
analyzed in Guava easyCyteTM5HT flow cytometer (Merck Millipore). 
 
2.7. Quantification of mycobacteria intracellular survival 
 
Mø were seeded in 96-well plates at a density of 5 x 104 cells/well and infected with 
mycobacteria, as previously described. After 3 h, 1, 3 and 5 days of infection Mø were incubated in 100 
μl of 0.05 % Igepal aqueous solution (Sigma) at 37 °C for 10-15 min to lyse host cells and release 
bacteria. Serial dilutions of the resulting bacterial suspensions were plated in Middlebrook 7H10 
supplemented with 10% OADC (Difco) and incubated for 2-3 weeks at 37° C before colonies were 
observable. When colonies became visible under the microscope, they were counted, and the formula N 
× Df ⁄ V was applied to calculate the number of CFU/ml, where N = number of colonies counted, Df = 
dilution factor regarding the initial suspension, and V = volume (ml) of inoculum used (5 μl in this case). 
 
2.8. Sandwich Enzyme-Linked Immunosorbent Assay (ELISA) 
 
The quantification of human IL-1β (Biolegend) in the supernatants of infected cells was 
performed by using Biolegend’s ELISA MAXtm Deluxe Sets and reagents and by following the 
manufacturer’s instructions. To stop the reaction, we used an acid solution 2N H2SO4 (Sigma). The 
absorbance was read by Tecan Infinite M200 Spectrophotometer at 450 nm and subtracted from the 
absorbance at 570 nm. 
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2.9. Treatment with SQV and RTV 
 
 Cells were pretreated 1 h with 5 μM of SQV and RTV kindly provided by Professor João 
Gonçalves (Instituto de Investigação do Medicamento, Faculdade de Farmácia da Universidade de 
Lisboa). The infection was performed as previously described, and the bacterial suspension was added 
over the treatment. After 1 h of infection the medium of infected cells were washed with PBS and fresh 
complete medium with 5 μM of SQV and RTV was added. The controls were treated in the same 
conditions but without addition of SQV and RTV. 
 
2.10. Statistical Analysis 
 
Data is presented as mean with the respective standard deviation or standard error (referred 
when used). Statistical analysis was performed with SigmapPlot 11. Multiple comparisons were made 
using one-way ANOVA followed by pairwise comparisons of the groups using Holm-Sidak test or 
Ranks. The considered nominal alpha criterion level was 0.05 below which differences between samples 
were considered significant. 
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3. Results 
 
3.1. Manipulation of cystatin C by siRNA during mycobacteria infection in 
macrophages 
The main objective of this study is to explore the potential of cystatin C manipulation to influence 
the immune response during mycobacteria infection. For this, we used strains of Mycobacterium bovis 
BCG and Mycobacterium smegmatis to perform our assays, as models of pathogenic and non-pathogenic 
bacteria related to M. tuberculosis. M. bovis BCG is an attenuated strain derived from M. bovis, the 
causative agent of bovine tuberculosis. However it activates the innate immune response and has similar 
properties to Mtb, making a suitable model to study the response to the virulent strains of mycobacteria 
13,69.  Mycobacterium smegmatis is a nonpathogenic strain saprophytic bacteria that conserves significant 
proportion of genes and physiological mechanisms similar to other mycobacteria such as Mtb 70,71. We 
selected M. bovis BCG because it is a non-virulent model of Mtb and M. smegmatis because it is a non-
pathogenic mycobacteria, and both are safe to handle outside a Biosafety level-3 laboratory that 
otherwise would be required to manipulate Mtb.  
 
3.1.1. Assessment of cystatin C mRNA silencing  
We performed an assay to assess the extent of cystatin C silencing by quantitative real-time 
polymerase chain reaction (qRT-PCR) to quantify the amplification of cystatin C mRNA. We 
transfected macrophages with siRNA anti-cystatin C to compare the extent of mRNA amplification to 
the one obtained from control cells treated with a scramble siRNA. 
 
  
Figure 3.1: Cystatin C expression in macrophages. Cystatin C levels in  macrophages were determine by real-time 
RT-PCR at 24 h postinfection after transfection with siRNA anti-cystatin C. Values are relative to non-infected cells transfected 
with scramble and are the average of biological duplicates. 
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As seen in Figure 3.1, the levels of cystatin C mRNA decrease approximately 50 % compara-
tively to the control. We hypothesize this achieved reduction in cystatin C expression will impact the 
cellular functions dependent on cathepsin activity.  
 
3.1.2. Cystatin C and the pro-inflammatory response  
 
The first step in M. tuberculosis infection is the encounter with innate immunity cells from the 
lung that recognize it by pattern recognition receptors. This first interaction leads to a production of 
chemokines and cytokines that recruit and activate other cells participating in the inflammatory re-
sponse. The interleukin-1β (IL-1β) is one of such mediators of inflammatory response, activated by the 
inflammasome in macrophages upon recognition of Mtb molecules 72. In order to evaluate the effects of 
cystatin C silencing in the proinflammatory response, we performed an Enzyme-Linked Immunosorbent 
Assay (ELISA) to measure the concentrations of IL-1β during M. bovis BCG and M. smegmatis infec-
tion. After 24 h of infection the supernatant was recovered for quantification of IL-1β. 
 
 
 
Figure 3.2: Silencing cystatin C increases the secretion of IL-1β in macrophages during infection. Primary human mac-
rophages were transfected with anti-cystatin C siRNA and infected with M. bovis BCG and M smegmatis. Following 24 h of 
infection the supernatant was collected and the concentration of IL-1β was measured by ELISA. Values are relative to non-
infected cells transfected with scramble control and represent the average of biological duplicates and the statistical significance 
is shown above the error bar (*p<0.05).  
 
It is notable a difference between the conditions in Figure 3.2. As expected the resting non-
infected cells show low secretion of IL-1β than the infected cells, confirming the ability of these cells 
to respond to infection. The M. bovis BCG infected cells show increased secretion of IL-1β  compara-
tively to M. smegmatis infection which is consistent with previous reports demonstrated the need for 
specific Mtb molecules to induce activation of the inflammasome and production of IL-1β 72. In both 
infections, silencing cystatin C resulted in an increase of IL-1β secretion although only statistically sig-
nificant for M. smegmatis infection. Interestingly, the increased the levels of IL-1β achieved by cystatin 
C silencing during M. smegmatis infection lead to a similar response to that M. bovis BCG alone.  
 
 – infected                                   
* 
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3.1.3. Cystatin C on the antigen presentation process during infection 
 
Processing and presentation of antigens derived from phagocytized pathogens by the MHC class 
II complex is crucial to elicit an effective cellular and humoral immune response and control Mtb infec-
tion. The immune activation and expansion of activated T cells is identified by highly HLA-DR expres-
sion which are well-recognized markers of TB 73. The expression of HLA-DR on the surface of macro-
phages indicates an ability to correctly assemble and express this type of antigen presentation machinery. 
Cathepsin S participates in antigen presentation by degrading the invariant chain that blocks HLA class 
II molecules from loading antigens. Pathogenic mycobacteria are reported to reduce the expression of 
HLA-DR class II molecules leading to lower activation of the adaptive immune response 24.  In order to 
analyze the result of cystatin C silencing on antigen presentation by macrophages we quantified the 
surface expression of a class II HLA molecule, HLA-DR, by flow cytometry after 24 h of infection with 
M. bovis BCG and M. smegmatis.  
 
 
Figure 3.3: Silencing cystatin C increases HLA-DR surface expression in M. bovis BCG and M. smegmatis infected 
macrophages. HLA-DR surface expression was assessed by flow cytometry after 24 h of M. bovis BCG and M. smegmatis 
infection of primary human macrophages previously transfected with siRNA anti-cystatin C or scramble control. Control non-
infected cells transfected with scramble are represented as 100% and the effect of cystatin C transfection and scramble was 
calculated as % of control. 
 
Following 24 h of infection, the results featured a reduction of HLA-DR surface expression in 
macrophages infected with M. bovis BCG (Figure 3.3, yellow bars) in agreement with previous reports 
for pathogenic mycobacteria. However, by silencing cystatin C we could restore the normal levels of 
HLA-DR expression (Figure 3.3, green bars) during M. bovis BCG infection or for the case of M. smeg-
matis we could even improve them.   
Cystatins inhibit cathepsins, and cathepsins are described to be involved in antigen presentation. In this 
assay, by silencing was observed an increase of HLA-DR expression on the cell surface indicating a 
correct assembly of the machinery of antigen presentation machinery. These results suggest that by 
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silencing cystatin C we are improving the proteolytic activity of cathepsins and consequently the pro-
cessing of the antigen presentation machinery.  
 
3.1.4. Role of Cystatin C on mycobacteria intracellular survival 
 
 Cystatin C is the main natural inhibitor of cathepsin S and other cathepsins and Mtb lowers 
cathepsin S expression during infection, which consequently, decreases the proteolytic activity and en-
hances Mtb survival 31. In this assay we want to determinate the role of cystatin C in the intracellular 
survival of Mtb in macrophages. To observe this interaction, we transfected macrophages with siRNA 
against cystatin C and infected macrophages with M. bovis BCG and M. smegmatis. Intracellular myco-
bacteria were accessed by colony-forming units (CFUs) after 3 h and 24 h post-infection. 
 
 
 
Figure 3.4: Cystatin C modulates M. bovis BCG and M. smegmatis survival in macrophages. Cells transfected with siRNA 
anti cystatin C were infected with M. bovis BCG (A), or M. smegmatis (B) for 3 h or 24 h and then lysed and plated in 7H10 
OADC medium. The intracellular mycobacteria were accessed by colony-forming units and the bar plots depict the average of 
biological triplicates. The standard error and the statistically significance comparatively to the control are shown for each time-
point (* p < 0.05). 
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As is shown in Figure 3.4, there is an increase of mycobacteria death by down-regulating 
cystatin C expression. The burden of bacteria is higher for M. bovis BCG at all time points, as is expected 
from a model for pathogenic mycobacteria. Nevertheless, by silencing cystatin C we could obtain the 
highest increase of mycobacteria killing in M. bovis BCG infected macrophages comparative with M. 
smegmatis infected macrophages at 3 h post infection (Figure 3.4 A and B). After 24 h post infection, 
we obtained similar results yet more pronounced for M. smegmatis infection than with M. bovis BCG 
infected macrophages. These results are in agreement with our hypothesis that by down-regulating 
cystatins expression we are improving the proteolytic activity and consequently increasing the 
mycobacteria death. 
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3.2. Impact of Proteases Inhibitors in macrophages during mycobacteria infection 
 
Tuberculosis and HIV infection have a significant overlap in various regions of the world. In 
this co-infection scenario, analyzing the interactions between the therapeutics and each infectious agent, 
gains particular interest. Moreover, previous studies revealed interactions between proteases inhibitors 
(PIs) used to treat HIV infection and cathepsins in HIV-infected macrophages 65. These PIs can bind the 
active site of proteases, inhibiting their activity, in similar fashion to cystatins. Taking this in consider-
ation, we hypothesize that these PIs might be used to manipulate the proteolytic activity during the 
infection of macrophages by mycobacteria. 
 
3.2.1. PIs and the pro-inflammatory response  
 
To assess if there is any interaction of PIs with proinflammatory response, we performed an 
ELISA to measure the concentrations of IL-1β during M. bovis BCG infection. The cells were treated 
with saquinavir or ritonavir 1 h prior infection at 5 μM concentration 54, and continued to be administered 
after infection. After 24 h of infection the supernatant was removed and IL-1β was quantified. 
 
 
 
Figure 3.5. Saquinavir and ritonavir alters the secretion of IL-1β in macrophages during infection. Primary human mac-
rophages were treated for 1h with 5 μM RTV, 5 μM SQV or left untreated (control) prior to infection with M. bovis BCG. (A) 
Represent non-infected macrophages and (B) represent M. bovis BCG infected macrophages Following 24 h of infection the 
supernatant was collected and the concentration of IL-1β was measured by ELISA. Values are relative to no treated cells and 
represent the average of biological duplicates ± standard deviation. 
 
In non-infected macrophages the concentrations of IL-1β are extremely low (Figure 3.5 A) 
which is expected since there is no stimulus for proinflammatory cytokines productions. In M. bovis 
BCG infected macrophages as seen in Figure 3.5 B, infected macrophages treated with RTV increased 
the concentration of IL-1β while infected macrophages treated with SQV decreased its concentrations.  
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3.2.2. Influence of saquinavir and ritonavir on antigen presentation process during M. 
bovis BCG infection. 
As previously mentioned, proteolysis is a crucial process for the processing and maturation of 
HLA class II antigen presentation complexes and the PIs are reported to interfere with host proteases. 
To evaluate the interference of PI with the antigen presentation process, we analyzed the surface expres-
sion of HLA-DR on M. bovis BCG infected cells. Infected macrophages were treated with saquinavir 
(SQV) and ritonavir (RTV) and the quantification of HLA-DR was accessed by flow cytometry 24 h 
post infection. 
   
 
Figure 3.6: Treatment with saquinavir and ritonavir alter the expression of HLA-DR on macrophages surface. Cells 
were treated for 1h with 5 μM RTV, 5 μM SQV or left untreated (control) prior to infection with M. bovis BCG. The cells were 
treated until 24 h of infection. The HLA-DR surface expression was assessed by flow cytometry After 24 h of infection. Bar 
plots depict HLA-DR surface expression calculated as fluorescence intensity relative % to non-infected untreated control. This 
figure shows one representative experiment performed in duplicates ± standard deviation. 
 
 As seen in Figure 3.6, treatment with PIs interferes with the antigen presentation machinery 
during mycobacteria infections. In non-infected macrophages, both treatments enhance the HLA-DR 
expression comparing to the untreated control, however the expression of HLA-DR was higher in mac-
rophages treated with SQV than with RTV. In M. bovis BCG infected macrophages after 24 h of infec-
tion there is an increase of HLA-DR expression during SQV treatment. The macrophages treated with 
RTV showed a decrease of HLA-DR expression compared with untreated macrophages. Treatment with 
SQV proved to be more consistent between treated and untreated macrophages, while treatment with 
RTV shown differences between the treated and untreated macrophages. 
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3.2.3. Quantification of mycobacteria intracellular survival during treatment with 
saquinavir and ritonavir 
 
 After PIs shown interfere with antigen presentation machinery, recent studies shown the inter-
actions with proteolytic activity during infections. We used PIs as treatment to study their effects and 
quantify the intercellular survival of M. bovis BCG in macrophages. To this end, macrophages were 
pretreated with SQV and RTV followed by infection with M. bovis BCG. The intracellular mycobacteria 
were assessed by colony-forming units (CFUs) after 3 h, 24 h and 72 h of infection. 
 
 
Figure 3.7: SQV and RTV alters M. bovis BCG survival in macrophages. Macrophages were pretreated for 1 h with 5 μM 
RTV, 5 μM SQV or medium (control) followed by infection with M. bovis BCG for 3 h, 24 h and 72 h.  For each time point 
cells were lysed and plated in 7H10 OADC medium. The intracellular mycobacteria were assessed by counting colony-forming 
units and the bar plots depict the average of biological triplicates. The standard error and the statistically significance compar-
atively to the control are shown for each time-point (*p<0.003). 
 
 As seen in Figure 3.7, after 3 h of infection there were no changes in mycobacterial survival. 
Cells treated with SQV shown no significantly changes in the M. bovis BCG survival in any time-point, 
however cells treated with RTV increased survival after 24 h and 72 h of infection.  
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3.3. Silencing cystatin C during M. bovis BCG infection in macrophages treated with 
SQV and RTV 
 
In the previous sections I’ve shown that cystatin C silencing or PIs treatment can be used to manip-
ulate the infection. Following those positive results we decided to combine both strategies and analyze 
the outcome. To perform this assay, first we transfected macrophages with siRNA against cystatin C, 
followed treatment with SQV or RTV 1 hour before infection, and finally infected cells with M. bovis 
BCG. 
 
3.3.1. Quantification of mycobacteria intracellular survival in siRNA anti cystatin C 
transfected macrophage, treated with SQV and RTV 
 
As previously reported, proteolytic activity plays an important role against pathogens during 
infections 74. PIs and cystatins interfere with proteolytic activity and our results proved they can influ-
ence mycobacteria death during infection. Following our promising results, we performed an assay 
where we transfected macrophages with siRNA anti-cystatin C and then treated them with saquinavir or 
ritonavir before infecting with M. bovis BCG. The results of mycobacteria intracellular survival were 
accessed by CFUs 3h, 1, 2 and 5 days post infection. 
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Figure 3.8: Silencing cystatin C and treatment of macrophages with SQV or RTV alters mycobacteria survival. Cells 
were transfected with siRNA anti cystatin C and in the next day were pretreated for 1 h with 5 μM RTV, 5 μM SQV or medium 
(control). After that, macrophages were infected with M. bovis BCG. The intracellular mycobacteria were accessed by colony-
forming units at 3 h (B), 1 (C), 3 (D) and 4 (E) days postinfection by lysing the cells and plating the lysate in 7H10 OADC 
medium. The bar plots depict the average of biological triplicates.  
 
 As seen in Figure 3.8 A, the different treatments affect the mycobacterial survival. The SQV 
treatment enhanced mycobacterial killing while RTV treatment increased mycobacteria survival, with 
or without silencing cystatin C. Silencing cystatin C together with SQV produced the greatest increase 
of M. bovis BCG death. 
The different behavior of macrophages starts after 1 day of infection (Figure 3.8 B). As previ-
ously seen in our results with singular treatments with PIs, in the presence of RTV, is shown an increase 
of mycobacterial survival in transfected macrophages with scramble and cystatin C, while in SQV pres-
ence, the mycobacterial survival is similar to the  infected macrophages without treatment.  
 After 3 and 4 days of infection (Figure 3.8 D and E) we could observe an increase of M. bovis 
BCG death in macrophages transfected with cystatin C and treated with SQV. This impact of silencing 
cystatin C and treated them with SQV reinforce our previously results where we observed an increase 
of mycobacteria death by silencing cystatin C (Figure 3.4 A) and also suggesting SQV increase the 
proteolytic activity. 
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 During the 4 days of infection there is a significant difference between macrophages treated 
with RTV than the others treatments. RTV and silenced cystatin C in macrophages increase the myco-
bacteria survival over time, suggesting that RTV can keep is action and favor the proliferation of infec-
tion.  
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4. Discussion 
 
 
 
In the first part of this thesis the effects of silencing cystatin C on the proinflammatory re-
sponse are analyzed. The proinflammatory cytokines are important against pathogens. Macrophages 
produce IL-1β, a proinflammatory cytokine mediator of inflammatory response, which is activated by a 
cysteine protease called caspase-1, whose activity is dependent on the activation of the inflammasome 
75,76. Its involved in cell proliferation, differentiation and apoptosis 77,78. Was discovered that high levels 
of IL-1β leads to inhibition of Mtb growth by promoting additional antimicrobial effectors which restrict 
Mtb replication 79.  
One other class of proteases is involved in an alternative-processing pathway to the maturation 
of IL-1β, the serine proteases 80. Published reports used inhibitors of serine proteases during Mtb infec-
tion to evaluate the secretion of IL-1β. The use of inhibitors led to a decreased IL-1β secretion, and the 
authors demonstrated the manipulation of serine proteases was not correlated with cell death during Mtb 
infection 81. Since inhibitors of serine proteases alter IL-1β secretion, we wanted to see if by manipulat-
ing the inhibitors of cysteine proteases, cystatins, we would produce such effect in IL-1β secretion. We 
down-regulated cystatin C expression using siRNA anti-cystatin C to quantify IL-1β secretion during 
M. bovis BCG and M. smegmatis infections and if is correlated with mycobacteria survival. While down-
regulating the expression of cystatin C during infection there was an increase of IL-1β secretion for both 
infections (Figure 3.2) in contrast with the reaction of the proinflammatory response with the use of 
serine proteases inhibitors previous reported 81. Curiously, the basal levels of IL-1β secretion were lower 
during M. smegmatis infection than during M. bovis BCG infection, yet this is consistent with previous 
reports that demonstrated the need for specific Mtb molecules to induce activation of the inflammasome 
and production of IL-1β 72. Nevertheless, by silencing cystatin C we could restore the levels of IL-1β to 
those observed for M. bovis BCG infection. It is possible that serine proteases are also involved in the 
enhanced of IL-1β secretion, as was previously mentioned 81, and help in the restoration of proinflam-
matory response. Since M. smegmatis is a non-pathogenic saprophyte, it’s possible other mechanisms 
are involved and enhance the secretion of IL-1β in macrophages. The increase of IL-1β is a strong indi-
cator of inflammasome activation against the mycobacteria infection.  
 
 The observation that cystatin C silencing provoked an increased pro-inflammatory response 
prompted us to search for other crucial aspects of the immune response to infection that might also be 
modulated by cystatin regulation. One such aspect is the priming of adaptive immunity by an effective 
presentation of microbial antigens by phagocytes to lymphocytes. We proceeded to search for an inter-
action with the antigen presentation machinery by analyzing if the class II antigen presentation com-
plex HLA-DR is being correctly expressed on the surface of infected macrophages.  
Cystatin C is the major regulator of cathepsin S and cathepsin S takes an important role in anti-
gen presentation since it degrade the invariant chain of the HLA class II complex 82. The expression of 
antigen-loaded HLA class II complex leads to an activation of T cells. The presence of HLA-DR is an 
indicator of macrophage’s ability to present antigens and is one way to confirm the antigen presentation 
machinery is being correctly  assembled 83–86. 
Previous evidence has suggested that cystatin C has no control on MHC class II (the murine 
equivalent of the human HLA class II) in dendritic cells 87. However, since cathepsin S allows HLA 
class II molecules to load antigens, we wanted to know if the inhibition of cystatin C and consequent 
interference with the proteolytic activity of cathepsins alters antigen presentation. 
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Silencing cystatin C alters the expression of HLA-DR on the cell surface in both, M. bovis BCG 
and M. smegmatis infected macrophages, as seen in Figure 3.3. By inhibiting cystatin C we restored the 
normal levels of HLA-DR expression in M. bovis BCG infection, and in M. smegmatis was observed an 
improvement of HLA-DR levels.  
Other studies support the degradation of the invariant chain of MHC class II is dependent on 
cathepsin L or S activity, as well as the peptides presented by MHC class II 88–90. One possible explana-
tion to the restoration of the HLA-DR levels during infection is that by silencing cystatin C we are 
increasing  the activity cathepsin S and of other cathepsins and improving the antigen presentation ma-
chinery and possibly improve the activation of T-cells which is deficient during Mtb infection.  
 
The results from intracellular survival complement our previous results from proinflammatory 
response and antigen presentation. Using siRNA anti cystatin C, in the initial phase of M. bovis BCG 
infection was observed an increase of mycobacteria killing, but the effect decreased during infection, 
however still visible the mycobacteria death when cystatin C is silenced compared with the control 
(Figure 3.4 A). The same result was observed during M. smegmatis infection, being more pronounced 
the mycobacteria killing after 3 h of infection than 24 h of infection (Figure 3.4 B).  
In the initial phase of infection, the macrophages already internalized the bacteria and the many 
steps of phagocytosis initiate. The most important step for bacteria killing is the phagosome fusion with 
late endosomes and lysosomes, forming a structure called phagolysosome which carries in its lumen a 
high content in cathepsins and activates them due to pH decrease 27,31,91.  
Previous reports demonstrated interactions between cathepsins and Mtb: cathepsin L levels de-
crease in response to infection of IFN-γ-stimulated mouse bone marrow macrophages with Mtb 92, and 
down-regulation of cathepsin G was found to increase Mtb survival in THP1 cells 28. 
Cathepsins such as cathepsin B, L and S, play an important role in pathogen killing and antigen 
presentation. Published reports shown a decrease of cathepsin B, L and S activity during Mtb and M. 
smegmatis infection in macrophages, leading to an increase of mycobacteria survival. These results 
showed the importance of the proteolytic activity of cathepsins against mycobacteria. The same study 
reports a down-regulation of cystatin C upon infection what was unexpected since cystatin C is a natural 
inhibitor of cathepsin B, L and S and was observed the down-regulation of these cathepsins during Mtb 
infection 31. Our results shown an increase of mycobacteria killing by reduction of the expression of 
cystatin C during infection, what was expected since cystatins inhibits cathepsins. In fact, cystatin C is 
the major inhibitor of cathepsin S 49,93,94. It is possible that silencing cystatin C leads to up-regulation of 
cathepsin S activity for its main functions such as: pathogen killing, that is observed in our results of 
increased mycobacteria killing; degradation of invariant (Ii) chain which allows HLA class II molecules 
to load antigens, and in our experiments resulted in a restoration of HLA-DR expression on infected 
macrophages. However, while I’m inferring that the direct responsible for these changes is cathepsin S, 
other intermediate or effectors might be at play. More assays are needed to quantify the expression and 
activity of cathepsin S in cystatin C silenced macrophages and to test if cathepsin S is in fact important 
for the phenotypes here described to occur. 
 
 
 As mentioned before, cystatins are the natural inhibitors of cathepsins by binding the active site 
inhibiting cathepsins activity. There are also other inhibitors of proteases in nature and synthesized in 
laboratory 95. In the case of tuberculosis, there is a type of inhibitor that often co-exists with bacterial 
infection, such as those used in HIV therapy, whose co-infection is significantly prevalent. 
Protease inhibitors (PIs) used in HIV therapy, act similarly to cystatins, they block the active 
site of proteases inhibiting their activity. PIs are used to block HIV aspartyl protease, thus inhibiting the 
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cleavage of the polyproteins Gag and Gag-Pol of HIV and preventing the maturation of non-infectious 
immature virions, to mature infectious virions 96,97. In the second part of this thesis I analyze M. bovis 
BCG infected macrophages exposed to treatment with PIs, specifically saquinavir and ritonavir, since it 
was recently demonstrated that SQV and RTV modulate cathepsin S activity 54. Following my presented 
evidences that cystatin manipulation can alter the macrophage response to mycobacterial infection, my 
second goal was to understand the influence in those immune processes of PIs used to treat HIV infection 
that have the potential to regulate proteolysis. Once again I focused on the ability of the macrophage to 
signal a proinflammatory response, engage the antigen presentation mechanisms and kill the bacterial 
pathogen. 
 
The proinflammatory cytokines are important against pathogens. Previous reports demon-
strated that SQV treatment in non-infected macrophages in vitro, leads to an increase of IL-1β produc-
tion 98. SQV interfere with proinflammatory cytokines therefore we wanted to observe if the same re-
sponse occurs in infected macrophages. By analyzing our results from proinflammatory response, in 
non-infected macrophages the secretion of IL-1β is almost null compared with the infected macro-
phages. In the infected macrophages there is an increase of secretion of IL-1β in cells treated with RTV 
(Figure 3.5), that might be due to high number of bacteria stimulating the immune response, which later 
is confirmed in the results obtained by mycobacteria survival. However, the SQV treated macrophages 
has lower concentrations of IL-1β compare with RTV treated macrophages (Figure 3.5) and the concen-
trations of IL-1β from silenced cystatin C (Figure 3.2). These results suggested that SQV, RTV and 
silenced cystatin C could interfere with the proinflammatory response in different ways. 
 
SQV and RTV can alter peptide degradation patterns modifying the epitope production and 
consequentially the MHC class I complex, and modify the antigen processing 66. Since PIs influence the 
MHC class I complex, we verify if they influence the proteolytic activity of cathepsins and their inter-
action with the MHC class II complex and the antigen presentation. To find out, we analyzed the 
expression of HLA-DR on the macrophages surface.  
SQV enhances the proteolytic activity of cathepsin S, as was recently described 54, which has 
an important role in processing antigen peptides and the MCH class II complex. Our results confirm that 
interaction by the increase of HLA-DR expression in cells treated with SQV (Figure 3.6) suggesting the 
proteolytic activity was enhanced, and that macrophages have correctly processed the antigen presenta-
tion machinery to prime T cells. In contrast, the expression of HLA-DR on macrophages surface was 
lower in RTV treatment. The decrease of the proteolytic activity and consequently the pool of antigen 
presentation complexes is a possible explanation to this contrast. However, the results from SQV treat-
ment have similarities with the results of HLA-DR expression in infected macrophages silenced with 
cystatin C (Figure 3.3). 
 
These results are correlated with the intracellular survival of M. bovis BCG where we observe 
a decrease of M. bovis BCG survival in cells treated with SQV (Figure 3.7), which explains the increase 
of HLA-DR expression. This immune response was very similar to what was observed in the previous 
results for silencing of cystatin C. In contrast, an increase of M. bovis BCG survival during RTV treat-
ment (Figure 3.7), which correlated to lower surface expression of the antigen presentation. SQV and 
RTV are reported to differentially control the proteolytic activity by respectively increasing or decreas-
ing its activity 54, and our results fit these evidences. These PIs also control cathepsin S activity which 
is involved in the invariant chain (iI) processing of MHC class II and in the bacteria degradation. The 
decrease of Cat S favors bacteria survival as was previously shown 31, this makes Cat S one possible 
responsible for the alteration in the expression of HLA-DR and the levels of M. bovis BCG survival that 
were observed during PI treatment.  
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 Our previous results were very suggestive that by manipulating cystatin C expression or by 
using and PIs we can improve the immune response mediated by macrophages possibly by manipulating 
the proteolytic activity of cathepsins. Since both methods individually appear to produce similar results, 
we decided to perform an assay in which we employ both, by silencing cystatin C while treating with 
SQV or RTV in infected macrophages. 
The previous results related with cystatin C suggested the silencing of cystatin C during infec-
tion may improve the killing of mycobacteria since the targets of cystatin C, namely cathepsins, would 
be free to perform their proteolytic activity. The treatments with PIs suggested that SQV, described for 
improving the proteolytic activity of cathepsin S enhances mycobacteria killing while in contrast, RTV 
described for decreasing the activity of cathepsin S increases mycobacteria survival54. 
In this last experiment, as single treatments, SQV and silencing cystatin produced the same 
results, increasing M. bovis BCG killing. When we combined both treatments we could see a synergistic 
improvement of bacterial killing mostly relevant for the latter stages of the infection (Figure 3.8 D and 
E). Since on one treatment we are lowering a cathepsin inhibitor and on the other treatment we are using 
an enhancer of cathepsin activity we might be further increasing the lysosomal proteolytic response 
leading to the destruction of the pathogen. In contrast, RTV treatment with silenced cystatin C showed 
the highest increase of M. bovis survival in all phases of infection (Figure 3.8). In our previous results 
macrophages treated with RTV increased the mycobacteria survival while silencing cystatin C increased 
their death. The RTV treatment together with silenced cystatin C, seems to nullify the effect of silencing 
cystatin C, increasing the mycobacterial survival. Possibly RTV could be interacting not only with pro-
teolytic activity of cathepsins but also with other mechanisms that favor of mycobacteria survival. How-
ever, these results together demonstrate the capacity of PIs and silenced cystatin C in manipulating the 
immune response against the mycobacteria.  
In short, silencing cystatin C led to: (I) an increase proinflammatory cytokines activated by the 
inflammasome against the mycobacteria, (II) a restore of HLA-DR expression on macrophages surface 
and (III) an improvement of mycobacteria killing. Altogether, these results consistently reinforce the 
idea that lowering the expression of the cathepsin inhibitor, cystatin C, improves the host cellular re-
sponse to infection. 
For PIs treatments was shown by conjugating ours results from proinflammatory response, an-
tigen presentation and mycobacterial survival, that PIs from HIV therapy interact with the cathepsins 
activities during mycobacteria infection. They may blind directly to the catalytic site of cathepsins and 
inhibit the activity, or maybe they are involved in other pathways which might alter cathepsins activities 
and decrease or increase their activities against the bacteria. 
We can also say silencing cystatin C as the same actions in the immune system as SQV, and 
both together could improve the immune system response against the bacteria. 
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5. Final considerations and future perspectives 
 
M. tuberculosis is able to avoid the defense mechanism of macrophages, one of them the proteolytic 
activity of cathepsins. In this thesis we use two different strategies that act on proteolytic activity to see 
what changes could occur in host cells against mycobacteria: the first, through a host molecule itself, 
cystatin C, and the second, through molecules external to the system, proteases inhibitors from HIV 
treatment, saquinavir and ritonavir. 
From the results obtained in the analysis of manipulating cystatin C, we may conclude that during 
mycobacteria infection in macrophages manipulating cystatin C may have had an impact on the 
proteolytic activity of cathepsins. Since cystatin C is the major inhibitor of cathepsin S activity, possibly, 
the silencing of cystatin C led to an increase of cathepsin S which intervening in the antigen presentation 
machinery and pathogens death. 
 The next step is to confirm the involvement of cathepsin S in these results, by analyze the activity 
and expression of its during silencing of cystatin C. It is also needed an analysis of other cathepsins and 
their involvement against mycobacteria infection during cystatin C silence. In future experiments we 
need try to understand the triggering of events when we silence cystatin C, from the moment the 
macrophage comes into contact with mycobacteria, until the end of the infection. However, we proved 
the manipulation of cystatin C led to changes in the immune response against the pathogen, opening 
new doors of study and possible development of new therapies against Mtb. 
The use of PIs used in HIV therapy in mycobacteria infections suggested an interaction with the 
immune system response. They altered the secretion of proinflammatory cytokines, and also interfere 
with antigen presentation machinery and pathogen death. Treatments with SQV prove to increase the 
mycobacteria death while RTV decreases mycobacteria death, which may suggest an interaction with 
the proteolytic activity but the answer is still unknown. Studies demonstrated interactions with these PIs 
with cathepsin S 65 it is needed to performed more assays to verify the cathepsin S activity and if others 
cathepsins are also being influenced by the PIs. These treatments need to be further studied to see which 
other immune system pathways may be involved during mycobacteria infection. Yet, treatment with 
SQV proved to be viable pathway to improve the immune system against the pathogens.  
 
This study supports the initial hypothesis that by interfering with cystatins we are capable to help 
the host macrophages against the pathogenic mycobacteria and thus improve the cellular response 
against the infection. In addition, treatments with SQV can also help the immune system recover their 
sets of weapons against pathogenic mycobacteria. These two systems could be used as a tool to 
developing new drugs or therapies that improves the immune system response through cathepsins 
activity which are important against Mtb infection. 
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